Technology
Health
Biotechnology

Veracyte

$24.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.28%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Veracyte and other stocks, options, ETFs, and crypto commission-free!

About

Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. Read More It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Employees
270
Headquarters
South San Francisco, California
Founded
2008
Market Cap
1.02B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
470.51K
High Today
$24.97
Low Today
$24.26
Open Price
$24.71
Volume
222.78K
52 Week High
$26.80
52 Week Low
$7.05

Collections

Technology
Health
Biotechnology
Cancer Prevention
2013 IPO
US
North America
Female CEOs

News

Yahoo FinanceMay 11

Hedge Funds Have Never Been This Bullish On Veracyte Inc

Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals.

88
Yahoo FinanceMay 9

Veracyte to Present at the UBS Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on Monday, May 20, 2019 at 9:30 a.m. EDT. The link to the live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be...

24
BusinessWireMay 7

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $23.25 per share. The net proceeds to Veracyte from the offering were approximately $137.9 million, after deducting underwriting discounts and commissions and estimated offering expenses. Morgan Stanley & Co. LL...

53

Earnings

-$0.27
-$0.20
-$0.12
-$0.05
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 22, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.